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This investigation was undertaken in order to elucidate he human enzymes which participate in metabolism of the double bonds of unsaturated 
fatty acids during B-oxidation. The results indicate that the human monofunctional d3, d2-enoyl-CoA isomerase (EC 5.3.3.8) with the native M, 
of 70,000 differed significantly from its rat counterpart [Palosaari et al. (1990) J. Biol. Chem. 265, 3347-33531; the isoelectric point of the human 
isoform was over three pH-units more acidic, it showed different chromatographic behaviour, the human enzyme did not show any clear-cut 
substrate chain-length specificity and only a weak immunological cross-reactivity was detected with the antibody to rat liver mitochondrial 
short-chain enzyme. This explains the failure of attempts to apply the rat data directly to human beings. Another isomerase activity from human 
liver was found to be a part of the isomerase-hydratase-dehydrogenase polypeptide showing immunological cross-reactivity with the previously 
characterized peroxisomal multifunctional enzyme (MFE) from rat liver. 
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1. INTRODUCTION 
Our understanding of the biochemistry and physiol- 
ogy of both eukaryotic mitochondrial and peroxisomal 
B-oxidation is currently extending rapidly and is under 
continuous re-evaluation. Epimerization of 3-hydroxy- 
acyl-CoAs appears to occur by the combined action of 
two stereospecific hydratases, employing a dehydra- 
tion-hydration mechanism via trans-2-enoyl-CoA inter- 
mediates [l-3]. Recently, a novel pathway has been pro- 
posed for the metabolism of dcis-5-enoic acids, namely 
the reduction of their CoA-esters directly to saturated 
acyl-CoAs [4]. New aspects also include the demonstra- 
tion of the presence of a multifunctional B-oxidation 
enzyme (MFE) in mitochondria [5,6] and the finding 
that j&oxidation in yeasts proceeds via D-3-hydroxy- 
CoAs but not via L-3-hydroxyacyl-CoAs [7]. 
One characteristic of B-oxidation enzymes is the oc- 
currence of multiple isoforms. This situation is exempli- 
fied by the separate inborn errors in the isoforms of 
three mitochondrial acyl-CoA dehydrogenases [8-l l] 
and two peroxisomal acyl-CoA oxidases [12,131. In line 
with this generalization, separate isomerases have been 
described in rat liver to date [ 141. Only a limited number 
of experiments have been carried out so far regarding 
the auxiliary enzymes of /?-oxidation in humans, how- 
ever, which is surprising in view of the important nutri- 
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tional role which (poly)unsaturated fatty acids play in 
human well-being. The only recognized inborn error in 
humans affecting the enzyme systems degrading unsatu- 
rated fatty acids is the reductase defect, which is de- 
scribed as being lethal at an early age [15]. 
In order to characterize the p-oxidation of unsatu- 
rated fatty acids in humans we began to purify A3, A2- 
enoyl-CoA isomerase. The present work shows that the 
human liver contains at least two isoforms of A3, A2- 
enoyl-CoA isomerase: a monofunctional enzyme with a 
native M, of 70 000, which is apparently a mitochondrial 
protein and a peroxisomal isomerase forming part of a 
MFE. 
2. MATERIALS AND METHODS 
2.1. Reagents and chemicals 
L-3-Hydroxyacyl-CoA dehydrogenase (EC 1.1.1.35), 4-chloro-l- 
naphthol, catalase (EC 1.11.1.6) (from bovine liver), dithiothreitol 
(DTT), bovine serum albumin (BSA), EDTA and EGTA were pur- 
chased from Sigma Chemical Co., St. Louis, MO, USA; NAD’, coen- 
zyme A, lactate dehydrogenase (EC 1.1.1.27) (from rabbit muscle), 
cytochrome c (from horse heart, type III) and malate dehydrogenase 
(EC 1.1.1.37) (from pig heart) from Boehringer Mannheim GmbH, 
Mannheim, Germany; Matrex gel red A from Amicon Corp., Lexing- 
ton, MA; Sephacryl S-200 HR, protein A-Sephadex, phenylsepharose 
CL4B, Blue dextran and Pharmalyte pH 3-10 from Pharmacia LKB 
Biotechnology AB, Uppsala, Sweden; hydroxyapatite and goat 
anti-rabbit IgG from BioRad Laboratories, Richmond, CA, USA; 
Freund’s adjuvants from Difco Laboratories, Detroit, MI, USA, ben- 
zamidine hydrochloride hydrate (BA) and phenylmethylsulfonyl fluo- 
ride (PMSF) from Aldrich-Chemie, Steinheim, Germany and polyeth- 
ylene glycol20,OOO from Fluka Chemie, Buchs, Switzerland. 2-Enoyl- 
CoA hydratase 1 (crotonase) (EC 4.2.1.17) was purified from rat liver 
according to Furuta et al. [16]. 
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2.2. Acyl-CoA esters 
Acyl-CoA esters were synthesized by the mixed anhydride method 
[17] and purified on thin layer cellulose plates [18]. Trans-3-enoyl acids 
which were not commercially available were synthesized according to 
Boxer and Linstead [19]. 
2.3. PuriJcation of human isomerases 
12 g of frozen human liver tissue was homogenized with an Ultra- 
Turrax tissue disruptor in a 5-fold volume of 5 mM potassium phos- 
phate, 0.5 mM EDTA, 0.5 mM EGTA, 0.5 mM BA, 0.5 mM DTT 
and 0.1 mM PMSF, pH 7.0 and subsequently ultracentrifuged at 
100,000 x g for 1 h. Unless not stated otherwise, the supernatant was 
heat-treated at 60°C for 2 min. The sample was centrifuged at 
10,000 x g for 10 min and the supernatant ( otal volume of 40 ml) was 
mixed into sucrose and applied to a 110 ml Ampholine LKB electro- 
focusing column to form a 5-50% sucrose density gradient containing 
1% (v/v) of Pharmalyte, pH 3-10. After a run for 20 h at +4’C, the 
column was unloaded and the collected fractions were assayed for 
isomerase. The isomerase containing sample was dialyzed overnight 
against 2 x 2 litres of 20 mM potassium phosphate, 0.5 mM EDTA, 
0.5 mM EGTA, 0.5 mM BA, 0.5 mM DTT, pH 7.0 (buffer A). 
Ammonium sulphate was added to a sample to a final concentration 
of 1.2 M and the sample was applied to a phenyl sepharose hydropho- 
bic column, 2.5 x 9 cm, in equilibrium with buffer A containing 1.2 M 
ammonium sulphate, and washed with 100 ml of the same buffer at 
a flow rate of 50 ml/h. A gradient from &60% ethylene glycol in buffer 
A (total volume 300 ml) was developed, followed by an additional 
wash with 60% ethylene glycol (50 ml). The pooled fractions were 
dialyzed against 2 x 2 litres of 20 mM potassium phosphate, 0.5 mM 
BA and 0.5 mM DTT, pH 7.0 (buffer B). The sample was applied to 
a Matrex gel red A column, 2.5 x 12 cm, in equilibrium with buffer 
B and washed with 100 ml of buffer B at a flow rate of 60 ml/h. A 
gradient from O-1.5 M KC1 in buffer B was developed (total volume 
300 ml). The fractions containing isomerase activity were dialyzed 
overnight against 2 litres of buffer B before applying to a hydrox- 
yapatite column, 1.6 x 5 cm, in equilibrium with buffer B. The column 
was washed with 75 ml of buffer B and a gradient from 20 to 500 mM 
potassium phosphate was generated (gradient volume 200 ml), the 
flow rate being 17 ml/h. Isomerase activity was measured, and the 
pooled fractions were concentrated with polyethylene glycol20,OOO to
a final concentration of 3 ml. The sample was applied to a S-200-HR 
gel filtration column, 2.5 x 125 cm, which was washed with 350 ml of 
200 mM potassium phosphate, 1 mM EDTA, 1 mM EGTA and 0.5 
mM DTT, pH 7.4 at a flow rate of 18 ml/h. Finally, isomerase activity 
was measured from the fractions. The human myocardial isomerase 
was purified by the protocol used for liver counterpart. The native 
molecular weights of the proteins were determined on a Sephacryl 
S-200-HR gel filtration column [20]. Protein concentrations were as- 
sayed with the BioRad protein assay reagent. It is worth mentioning 
that in our experience isomerase loses its catalytic activity rapidly 
during purification, especially if the protein concentration is low. 
When non-heat reated human liver extract was applied to a Matrex 
gel red A, two peaks of isomerase activity were found (eluting at 0.1 
M and 0.9 M KCl). The high salt activity was purified according to 
Palosaari and Hiltunen [21] and proved to be a peroxisomal MFE. 
2.4. Antibodies and immunoblotting 
A protein A-Sephadex column was used to purify the IgG fraction 
of antiserum for rat liver short-chain isomerase [20]. In immunoblot- 
ting the proteins from the SDS-PAGE [22] were transferred electro- 
phoretically onto nitrocellulose and detected using the anti-isomerase 
IgG as the primary antibody, goat anti-rabbit IgG with horseradish 
peroxidase as the second antibody [23] and 4-chloro-1-naphthol for 
staining. 
2.5. Others 
Human heart and liver tissues were obtained from forensic autop- 
sies performed less than 12 h after death. The material for the success- 
ful purification was obtained from an accidental death due to submer- 
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sion in icy water. The use of human tissues was approved by the 
Bureau of Medicine in Finland. Permission for the animal experiments 
was granted by the University of Oulu Committee on Animal Exper- 
imentation. 
3. RESULTS 
3.1. Electrofocusing experiments 
Electrofocusing of the ultracentrifuged non-heat- 
treated human liver extract separated the isomerase ac- 
tivity into two peaks (Fig. 1). The immunoblotting ex- 
periment showed that the antibody to rat liver short- 
chain isomerase recognized a mildly acidic isomerase 
(p1 of 6.1), but not a basic one (p1 of 8.7) (Fig. l), but 
the incubation time for staining had to be at least 5 
times longer when the same amounts of protein from 
human and rat extracts were used. The heat-treatment 
at 60°C for 2 min inactivated the basic isomerase activ- 
ity completely. The antibody to rat liver peroxisomal 
MFE recognized the latter isomerase, but not the acidic 
one (Fig. 1) indicating that the basic isomerase repre- 
sents human liver MFE. 
3.2. PuriJcation of isomerases from human liver 
The acidic human liver isomerase was purified to 
apparent homogeneity as described in detail in section 
2. The protocol gave a yield of 0.320 mg of purified 
protein starting from 12 g of human liver, the specific 
activity being 8.3 nmoYs*mg-’ of protein. A native mo- 
lecular weight of 70,000 was obtained by gel filtration 
on a S-200-HR column and SDS-PAGE analysis 
showed a subunit of 30,000 (Fig. 2B), indicating that the 
native enzyme is homodimeric. 
The isomerase activity purified above eluted from the 
linear gradient on Matrex gel red A at 0.1 M KCl. 
Another isomerase activity from non-heat-treated 
human liver extract (20 g of frozen liver), was purified 
following the protocol described for the rat enzyme [21] 
with a yield of 0.23 mg, specific activity 5.0 nmoYs.mg-’ 
of protein. The molecular weight corresponded to that 
of the human bifunctional enzyme [24]. The subunit size 
was 78,000 on SDS-PAGE indicating that it is monom- 
eric enzyme (Fig. 2C). The antibody to rat liver MFE 
cross-reacted with the corresponding human liver pro- 
tein (Fig. 1). When this monomeric enzyme was incu- 
bated with trans-3-enoyl-CoA in the presence of NAD’, 
but without 2-enoyl-CoA hydratase 1 or 3-hydroxyacyl- 
CoA dehydrogenase, NADH was generated. These data 
show the isomerase to be a multifunctional isomerase- 
hydratase-dehydrogenase nzyme. The isomeriza- 
tion:hydration:dehydration velocity ratio was 2: 18: 1, 
which is comparable to that of rat liver MFE when 
assayed with C,,-acyl-CoA-substrates. 
3.3. Characterization of the human myocardial A3,A2- 
enoyl-CoA isomerase 
The protein catalyzing isomerization was purified to 
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apparent homogeneity also from human myocardium 
extract (as indicated by the appearance of one band on 
SDS-PAGE; Fig. 2A) employing the methods used for 
purifying the acidic liver enzyme. The amount of puri- 
fied protein obtained from 20 g of human heart tissue 
was 0.840 mg (specific activity 8.60 nmol/min.mg-’ of 
protein) and the subunit weight of 30,000 was deter- 
mined by SDS-PAGE analyse. Gel filtration on a S-200- 
HR column gave a native A& of 70,000 indicating that 
it is a dimer. 
3.4. Kinetic studies 
The substrate specificities for human liver and heart 
isomerase were measured using different chain-length 
acyl-CoA-esters and the velocity ratios with tram-3- 
C,:C&,,-enoyl-CoA were 1:2.1:1.2 and 1:3.4:2.3, re- 
spectively. The corresponding values for peroxisomal 
MFE were 1:5.8:2.7. Since these values valued from the 
ones described for corresponding rat enzymes [20], we 
repeated the rat experiments in parallel. The experi- 
ments nevertheless agreed with the published data 
showing that the rat and human isomerases have differ- 
ent kinetic properties. Furthermore, separate experi- 
ments showed that an acidic isomerase from human 
liver and heart was not able to catalyze the reduction of 
NAD’ in the presence of trans-3-acyl-CoA esters alone, 
additions of 2-enoyl-CoA hydratase 1 and 3-hydroxy- 
acyl-CoA dehydrogenase being required. 
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Fig. 1. Separation and immunoblotting of two human liver isomerases by electrofocusing. 6 g of frozen liver tissue was homogenized in 10 mM 
potassium phosphate, 0.2 M KCl, 1 mM EDTA, 0.5 mM BA, 0.5 mM DTT, and 0.1 mM PMSF, pH 7.4, lo-fold (w/v) with an Ultra-Turrax tissue 
disruptor and centrifuged at 100 000 x g for 1 h. The supernatant was dialyzed overnight with 2 litres of 5 mM potassium phosphate, 0.5 mM BA 
and 0.5 mM DTT, pH 7.0. Two liver A’,&-enoyl-CoA isomerases were separated out in a 110 ml LKB electrofocusing column according to their 
isoelectric points as described in section 2. The column was unloaded by collecting fractions of 2 ml. The pH values and isomerase activity (shown 
by black dots) were measured from these fractions. The shaded areas denote absorbances measured at 280 nm. Immunoblottings of isomerase 
activity peaks are under the elution profile. Samples of 40 ~1 were taken from the fractions from the electrofocusing column and screened with 
the antibody to rat liver peroxidomal MFE (the upper panel) and the antibody to rat liver short-chain isomerase (the lower panel). 
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Fig. 2. Electrophoretic analysis of the purified human proteins on polyacrylamide gel. The following standards were used: phosphorylase b (97.5 
kDa), bovine serum albumin (66.2 kDa), ovalbumin (42.7 kDa), carbonic anhydrase (31 .O kDa), soybean trypsin inhibitor (21.5 kDa) and lysozyme 
(14.4 kDa); (2A) purified monofunctional isomerase from human myocardium (10 pug of protein), (2B) monofunctional isomerase from human liver 
(3 pg of protein) and (2C) multifunctional isomerase-dehydrogenase-hydratase prot in from human liver (15 yg of protein). 
4. DISCUSSION 
The present work demonstrates that the human being 
has at least two isoforms of d3J2-enoyl-CoA isom- 
erase:liver and heart monofunctional isomerase (M, 
70,000) and a peroxisomal isomerase (A4, 78,000) as a 
part of a MFE. The observation that the human liver 
and heart isoforms were similar was comparable to the 
situation with the corresponding rat isomerases [20]. 
The subunit size of the monofunctional isomerase was 
30,000 in both species, and they form a dimeric native 
enzyme. Furthermore, the antibody to the rat enzyme 
recognized its human counterpart (Fig. 1). There were 
differences between the rat and human enzymes, how- 
ever, the most striking of which was in their p1 values, 
the rat enzyme being basic (p1 9.5) and the human one 
mildly acidic (p1 6.1). The rat enzyme showed the high- 
est catalytic activity with short-chain substrates, and is 
therefore called a short-chain isomerase [20]. The corre- 
sponding human enzyme did not show any clear cut 
catalytic specificity regarding substrate chain length. 
The enzymes also showed different chromatographic 
behaviour during purification. In addition to different 
binding and elution from ion-exchanger columns the 
human monofunctional isomerase eluted from Matrex 
gel red A at a lower KC1 concentration (0.1 M) than the 
corresponding rat protein (0.2 M KCl) and from hy- 
droxyapatite column at lower KP, concentration than 
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the rat enzyme. A tetrameric isomerase has previously 
been demonstrated in hog liver [25], where four 
isoforms were found with p1 values varying from neu- 
tral to mildly acidic. We have described an isomerase 
activity with a native molecular weight of 200,000 by 
S-200-HR in rat liver [26]. When we put non-heat- 
treated human liver extract to a hydroxyapatite column, 
which was run as described [26], only two isomerase 
activity peaks were found. During the purification pro- 
tocol these activities showed to stand for an acidic 
monofunctional human isomerase and a peroxisomal 
multifunctional isomerase-hydratase-dehydrogenase 
enzyme. Thus the existence of another monofunctional 
isomerase in human liver, the counterpart of the rat 
liver mitochondrial long-chain isomerase [26], remains 
still an open question. 
The existence of several isoforms is typical of the 
enzymes of /?-oxidation, the only exception known to 
have a single isoenzyme so far being peroxisomal MFE 
[27,28]. The isoforms are thought to allow the flexibility 
required for metabolism of fatty acids of variable chain- 
lengths. The physiological function of the human 
monofunctional isomerase do not fit in with this pro- 
posal. It do not show any major kinetic differences with 
respect o substrate chain-length at least under the con- 
ditions tested here. The human MFE must originate 
from the peroxisomes, in view of its similarities to the 
Volume 322, number 3 FEBSLEmERS May 1993 
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Fig. 3. Immunological cross-reactivity of human d3d2-enoyl-CoA 
isomerases with rat antibodies. Proteins were detected by means of 
polyclonal antibodies as described in section 2. Immunoblotting with 
antibody to rat liver mitochondrial short-chain isomerase. (Lane 1) rat 
heart homogenate (300 pug of protein); (lane 2) rat liver homogenate 
(700 pg of protein); (lane 3) first isomerase activity peak from human 
heart on Matrex gel red A (60 pg of protein); and (lane 4) first 
isomerase activity peak from human liver on Matrex gel red A (45 pg 
of protein). 
corresponding rat protein and a proposal based on the 
same criteria can also made regarding the monofunc- 
tional isomerase, which is likely to be mitochondrial in 
origin. 
Our attempts to attribute the characteristics of rat 
isomerases to the corresponding enzymes in the human 
being were not very successful. Therefore the major aim 
of this study was to characterize these auxiliary enzymes 
of thep-oxidation of unsaturated fatty acids in humans. 
This work is required in order to deduce the primary 
structure of these proteins, to locate and characterize 
their genes and later on to screen for possible inborn 
errors affecting these enzyme systems in human. 
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